Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,588 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-in-Human, First-in-Child Trial of Autologous MSCs Carrying the Oncolytic Virus Icovir-5 in Patients with Advanced Tumors.
Ruano D, López-Martín JA, Moreno L, Lassaletta Á, Bautista F, Andión M, Hernández C, González-Murillo Á, Melen G, Alemany R, Madero L, García-Castro J, Ramírez M. Ruano D, et al. Among authors: hernandez c. Mol Ther. 2020 Apr 8;28(4):1033-1042. doi: 10.1016/j.ymthe.2020.01.019. Epub 2020 Jan 21. Mol Ther. 2020. PMID: 32053771 Free PMC article. Clinical Trial.
High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients.
Molina B, Alonso L, Gonzalez-Vicent M, Andion M, Hernandez C, Lassaletta A, Cormenzana M, Lopez-Ibor B, Villa M, Molina J, Diaz MA. Molina B, et al. Among authors: hernandez c. Pediatr Hematol Oncol. 2011 Mar;28(2):115-23. doi: 10.3109/08880018.2010.537434. Pediatr Hematol Oncol. 2011. PMID: 21299340
High-dose busulfan and cyclophosphamide as a conditioning regimen for autologous peripheral blood stem cell transplantation in childhood non-Hodgkin lymphoma patients: a long-term follow-up study.
Andion M, Molina B, Gonzalez-Vicent M, Alonso L, Hernandez C, Lassaletta A, Lopez-Ibor B, Villa M, Diaz MA. Andion M, et al. Among authors: hernandez c. J Pediatr Hematol Oncol. 2011 Apr;33(3):e89-91. doi: 10.1097/MPH.0b013e3181fd6c79. J Pediatr Hematol Oncol. 2011. PMID: 21358341
Glioblastoma, 47XXY/45,X mosaicism, and hyperpigmented skin lesions.
Bautista F, Fioravantti V, Hernández C, de Prada I, López-Pino MÁ, Ramírez M, Madero L, Moreno L. Bautista F, et al. Among authors: hernandez c. Pediatr Blood Cancer. 2018 Oct;65(10):e27299. doi: 10.1002/pbc.27299. Epub 2018 Jul 16. Pediatr Blood Cancer. 2018. PMID: 30010240 No abstract available.
ECLIM-SEHOP, a new platform to set up and develop international academic clinical trials for childhood cancer and blood disorders in Spain.
Bautista F, Cañete A, Ramírez-Villar GL, Fernández JM, Fuster JL, Diaz de Heredia C, Astigarraga I, García-Ariza M, Rives S, Dapena JL, Márquez C, Molinés A, Bermúdez MDM, Gallego S, Andrés MDM, Verdu-Amoros J, Hernández C, López M, Catalá A, Lassaletta Á, Cruz O, Ramírez M, Lendínez F, Carboné A, Gomez Sirvent J, Tallón M, Acha T, Moreno L, Fernández-Teijeiro A; Sociedad Española de Hematología y Oncología Pediátrica (SEHOP). Bautista F, et al. Among authors: hernandez c. Clin Transl Oncol. 2019 Dec;21(12):1763-1770. doi: 10.1007/s12094-019-02221-9. Epub 2019 Oct 9. Clin Transl Oncol. 2019. PMID: 31598904 Free article.
White paper: Understanding, informing and defining the regulatory science of microneedle-based dosage forms that are applied to the skin.
Dul M, Alali M, Ameri M, Burke MD, Creelman BP, Dick L, Donnelly RF, Eakins MN, Frivold C, Forster AH, Gilbert PA, Henke S, Henry S, Hunt D, Lewis H, Mistilis JJ, Park JH, Prausnitz MR, Robinson DK, Hernandez CAR, Shin J, Speaker TJ, Strasinger C, Taylor KMG, Zehrung D, Birchall JC, Jarrahian C, Coulman SA. Dul M, et al. Among authors: hernandez car. J Control Release. 2024 Nov 25:S0168-3659(24)00815-0. doi: 10.1016/j.jconrel.2024.11.056. Online ahead of print. J Control Release. 2024. PMID: 39603537
2,588 results